Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (ZNTL)

Q: What does CUSIP 98943L107 represent in this 13F holders report?

CUSIP 98943L107 is the security identifier for ZNTL - Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share used to aggregate holder disclosures.

Q: How many institutions held ZNTL - Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share in Q2 2022?

115 institutional investors reported ZNTL - Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share for Q2 2022. Use the holders table for investor-level position and value details.

CUSIP: 98943L107

Q2 2022 13F Holders as of 30 Jun 2022

Type / Class: Equity / Common Stock,$0.001 par value per share
Shares outstanding: 72,096,078
Total 13F shares: 58,254,677
Share change: +13,833,122
Total reported value: $1,636,896,016
Put/Call ratio: 1.5%
Price per share: $28.10
Number of holders: 115
Value change: +$359,446,058
Number of buys: 72
Number of sells: 54

Quarterly Holders Quick Answers

What is CUSIP 98943L107?
CUSIP 98943L107 identifies ZNTL - Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Related Filing Research

Latest 13F filings for newly reported positions.
Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
Latest 10-Q/10-K reports for financial context tied to this issuer.
Recent insider transactions for executive and insider activity.
SEC investors directory and top value investors for manager drilldown.
Back to full security ownership history.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2022
Previous quarter: Q1 2022

Recent filing periods for CUSIP 98943L107:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of ZNTL - Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
FMR LLC	13F	Company	9.4%	6,742,694	$311,109,000	—	31 Mar 2022	13F
Matrix Capital Management Company, LP	13F	Company	6%	4,349,279	$200,676,000	—	31 Mar 2022	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	5.8%	4,198,180	$193,704,000	—	31 Mar 2022	13F
VANGUARD GROUP INC	13F	Company	4.5%	3,240,585	$149,520,000	—	31 Mar 2022	13F
Avidity Partners Management LP	13F	Company	4.4%	3,176,999	$146,587,000	—	31 Mar 2022	13F
BlackRock Finance, Inc.	13F	Company	3.9%	2,842,580	$131,158,000	—	31 Mar 2022	13F
TYBOURNE CAPITAL MANAGEMENT (HK) LTD	13F	Company	3.4%	2,426,095	$111,940,000	—	31 Mar 2022	13F
STATE STREET CORP	13F	Company	2.9%	2,080,440	$95,992,000	—	31 Mar 2022	13F
VIKING GLOBAL INVESTORS LP	13F	Company	2.8%	2,026,656	$93,510,000	—	31 Mar 2022	13F
PRIMECAP MANAGEMENT CO/CA/	13F	Company	1.7%	1,208,590	$55,764,000	—	31 Mar 2022	13F
ALLIANCEBERNSTEIN L.P.	13F	Company	1.4%	996,759	$45,990,000	—	31 Mar 2022	13F
FEDERATED HERMES, INC.	13F	Company	1.3%	950,933	$43,876,000	—	31 Mar 2022	13F
EVENTIDE ASSET MANAGEMENT, LLC	13F	Company	1.1%	761,000	$35,113,000	—	31 Mar 2022	13F
Capital World Investors	13F	Company	0.95%	683,000	$31,514,000	—	31 Mar 2022	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.92%	666,064	$30,732,000	—	31 Mar 2022	13F
Anthony Y. Sun	3/4/5	President & CEO, Director	— class O/S missing	2,592,141	$26,672,095	—	04 Apr 2022	3/4/5
CITADEL ADVISORS LLC	13F	Company	0.71%	511,025	$23,578,000	—	31 Mar 2022	13F
PERCEPTIVE ADVISORS LLC	13F	Company	0.7%	501,509	$23,140,000	—	31 Mar 2022	13F
Allspring Global Investments Holdings, LLC	13F	Company	0.57%	410,081	$18,920,000	—	31 Mar 2022	13F
Polar Capital Holdings Plc	13F	Company	0.51%	369,329	$17,041,000	—	31 Mar 2022	13F
Fiera Capital Corp	13F	Company	0.51%	369,086	$17,029,000	—	31 Mar 2022	13F
NORTHERN TRUST CORP	13F	Company	0.47%	339,231	$15,652,000	—	31 Mar 2022	13F
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	0.4%	291,459	$13,447,000	—	31 Mar 2022	13F
Paradigm Biocapital Advisors LP	13F	Company	0.4%	287,577	$13,269,000	—	31 Mar 2022	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.39%	284,247	$13,115,000	—	31 Mar 2022	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.37%	267,837	$12,358,000	—	31 Mar 2022	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.37%	265,246	$12,238,000	—	31 Mar 2022	13F
Integral Health Asset Management, LLC	13F	Company	0.3%	215,000	$9,920,000	—	31 Mar 2022	13F
Affinity Asset Advisors, LLC	13F	Company	0.29%	207,500	$9,574,000	—	31 Mar 2022	13F
Ikarian Capital, LLC	13F	Company	0.28%	202,203	$9,329,000	—	31 Mar 2022	13F
MORGAN STANLEY	13F	Company	0.25%	177,838	$8,205,000	—	31 Mar 2022	13F
Bank of New York Mellon Corp	13F	Company	0.2%	143,603	$6,626,000	—	31 Mar 2022	13F
AXA S.A.	13F	Company	0.19%	133,393	$6,154,753	—	31 Mar 2022	13F
VOLORIDGE INVESTMENT MANAGEMENT, LLC	13F	Company	0.18%	131,940	$6,088,000	—	31 Mar 2022	13F
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	13F	Company	0.18%	129,771	$5,987,634	—	31 Mar 2022	13F
WELLS FARGO & COMPANY/MN	13F	Company	0.18%	128,418	$5,924,000	—	31 Mar 2022	13F
S.c.a. Candriam	13F	Individual	0.18%	127,964	$5,904,000	—	31 Mar 2022	13F
Nuveen Asset Management, LLC	13F	Company	0.16%	118,322	$5,792,000	—	31 Mar 2022	13F
Rafferty Asset Management, LLC	13F	Company	0.17%	121,170	$5,591,000	—	31 Mar 2022	13F
NEW YORK STATE COMMON RETIREMENT FUND	13F	Company	0.17%	119,277	$5,503,000	—	31 Mar 2022	13F
EcoR1 Capital, LLC	13F	Company	0.16%	115,236	$5,317,000	—	31 Mar 2022	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.15%	109,337	$5,045,000	—	31 Mar 2022	13F
TD ASSET MANAGEMENT INC	13F	Company	0.15%	105,903	$4,886,000	—	31 Mar 2022	13F
JPMORGAN CHASE & CO	13F	Company	0.15%	105,579	$4,871,000	—	31 Mar 2022	13F
Eversept Partners, LP	13F	Company	0.14%	100,187	$4,622,628	—	31 Mar 2022	13F
Invesco Ltd.	13F	Company	0.14%	97,455	$4,497,000	—	31 Mar 2022	13F
NORGES BANK	13F	Company	0.13%	94,750	$4,371,765	—	31 Mar 2022	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.13%	94,502	$4,360,000	—	31 Mar 2022	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	0.13%	91,502	$4,221,000	—	31 Mar 2022	13F
Ensign Peak Advisors, Inc	13F	Company	0.12%	83,526	$3,854,000	—	31 Mar 2022	13F

Institutional Holders of Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (ZNTL) as of Q2 2022

As of 30 Jun 2022, Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (ZNTL) was held by 115 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 58,254,677 shares. The largest 10 holders included Matrix Capital Management Company, LP, FMR LLC, VANGUARD GROUP INC, PRICE T ROWE ASSOCIATES INC /MD/, Avidity Partners Management LP, BlackRock Inc., STATE STREET CORP, TYBOURNE CAPITAL MANAGEMENT (HK) LTD, VIKING GLOBAL INVESTORS LP, and Decheng Capital Management III (Cayman), LLC. This page lists 115 institutional shareholders reporting positions in this security for the Q2 2022 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2022 vs Q1 2022 Across Filers

Q1 2022 holders

123

Q2 2022 holders

115

Holder diff

-8

Investor	Q1 2022 Shares	Q2 2022 Shares	Share Diff	Share Chg %	Q1 2022 Value $	Q2 2022 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.